#### Table 1 (supplement). Corneal and aqueous concentrations of topically applied fluoroquinolones

The extrapolated first quartile concentration provides a concentration that can be used to decide if the MIC of the isolated bacteria is expected to be above or below the anticipated concentration in the cornea and aqueous. If the MIC is below this first quartile concentration, it would be reasonable to expect the bacteria to be inhibited by that antimicrobial. Standard deviation (SD). # Based on the normal distribution of the concentrations, hence the mean, SD and quartile need to be interpreted with caution. Median used where available. Penetrating keratoplasty (PK), cataract surgery (CS).

Although the reported corneal concentrations of FQs are high, the associated standard deviations are also high. The coefficients of variance are high for ciprofloxacin, moxifloxacin, ofloxacin, levofloxacin and gatifloxacin, particularly in comparison to besifloxacin. This means that the concentrations achieved are not consistent around the mean. Because the actual data is not available in the listed references, the first quartile concentration has been extrapolated from the reported mean and standard deviation based on a normal distribution unless the median was available. Data is not available in articles so we cannot check the normality. The pharmacokinetics of the fluoroquinolones in corneal ulceration is unknown, so caution is needed in extrapolating the data.

Antimicrobial	Animal (A) /Human (H) model	Treatment Regimen	Epithelium intact or abraded	Mean Corneal Concentration (mg/kg) ±SD (median)	#First quartile concentration in Cornea (mg/kg)	Mean Aqueous Concentration (mg/L) ± SD (median)	#First quartile concentration in the aqueous (mg/l)	Ref
Ciprofloxacin 0.3%	Н	One drop at 30 min intervals 4.5-5h (8 doses) prior to PK	Intact	14.87 (7.41) mg/L	3.71	0.51 (0.42)	0.21	(1)
	Н	One drop 15 and 10 mins prior to PK	Intact	9.92 ± 10.99 (NA)	2.50	0.13 ± 0.23 (NA)	0	(2)
		Group 1: Home administration. One drop every 4h for 24h prior to PK	Intact	Group 1: 8.82 ± 8.24 (NA)	3.26	NA	NA	(3)
	Н	Group 2: Two drops applied by trained professional every 15 mins for 4h prior to PK	Intact	Group 2: 116.2 ± 336.94 (NA)	0			
		Group 3: Same as group 2	Group 3: Abraded	Group 3: 938.3 ± 1081.5 μg/g (NA)	208.29			
	Н	One drop every 15 mins for first hour then every hour prior to PK	Intact	5.28 ± 3.4 Range: 1.43 - 10.58 μg/g (NA)	2.99	NA	NA	(4)
		Group A: 1-2 drops four times a day for two days prior to CS.	Intact	NA	NA	Group A: 0.067 ±0.048 (NA)	0.035	(5)
	Н	Group B: 1-2 drops every 10 minutes in the hour prior to CS. Total of five doses.	Intact			Group B: 0.186 ± 0.131 (NA)	0.098	
		Group C: Combined regime of A and B.	Intact			Group C: 0.242 ± 0.207 (NA)	0.10	
	Н	One drop every 15 minutes for 4 doses prior to CS.	Intact	NA	NA	0.08 ± 0.113 (NA)	0.037	(6)

	Н	One drop every 15 minutes for 5 doses and then every 30 minutes for 3 doses before CS.	Intact	NA	NA	1.13 ± 1.90 (NA)	0	(7)
	н	Group 1: One drop at three 2hr intervals one day prior and three drops at 1h intervals on the day of CS.	Intact	NA	NA	Group 1: 0.127 ± 0.081 (Range 0.031 - 0.339)	0.072	(8)
		Group 2: One drop at 15 minute intervals, nine times, on the day of CS.	Intact			Group 2: 0.380 ± 0.328 (Range 0.33 - 1.388)	0.16	
	Н	Enucleated eyes immersed in Ciprofloxacin for 10 minutes	Intact	3.46 with standard error 0.512 (95% CI 2.60 - 4.61)	1.99	1.02 with standard error 0.142 (95% CI 0.78 - 1.34)	0.59	(9)
Moxifloxacin 0.5%		38 µL instilled  Group 1: After 10 minutes eyes removed.	Intact	Group 1: 18.60 ± 19.99 (NA) after 10 mins	Group 1: 5.11 After 10 mins	Group 1: 1.62 ± 0.04 (NA) After 10 mins	Group 1: 1.59 After 10 mins	(10)
	A	Group 2: After 1 hour eyes removed.		Group 2: 11.7 ± 6.50 (NA) after 1 hour	Group 2: 7.31 After 1 hour	Group 2: 1.68 ± 0.07 (NA) After 1 hour	Group 2: 1.63 After 1 hour	
	Н	Two drops administered three times prior to PK	Intact	12.66 ± 8.93 (10.53)	5.27	1.40 ± 1.17 (1.08)	0.54	(11)
	Н	One drop 60 mins prior to CS	Intact	NA	NA	0.67 ± 0.50 (0.49)	0.25	(12)
	Н	Enucleated eyes immersed in Moxifloxacin for 10 minutes	Intact	14.38 with standard error 1.886 95% CI (11.12 - 18.55)	9.62	4.78 with standard error 0.621 95% CI (3.69 - 6/.133)	3.21	(9)
Levofloxacin 0.5%	Н	One drop 15 and 10 mins prior to PK	Intact	18.23 ± 20.51 (NA)	4.39	0.37 ± 0.55 (NA)	0	(2)

	Н	Two drops administered three times prior to PK	Intact	5.95 ± 4.02 (5.24)	2.62	0.89 ± 0.86 (0.59)	0.30	(11)
		Group A: 1-2 drops 4x/day for 2 days prior to CS.  Group B: 1-2 drops every 10 minutes in the hour prior to surgery.	Intact Intact	NA	NA	Group A: 284.8 ± 193.2 (NA)	154.39 737.68	(5)
	Н	(Total 5 doses)  Group C: Combined regime A and B.	Intact			1135.6 ± 589.5 (NA) Group C: 1618.6 ± 779.8 (NA)	1092.23	
	Н	One drop every 15 minutes for 4 doses prior to CS.	Intact	NA	NA	0.728 ± 0.656 (NA)	0.511 (as reported in the paper)	(6)
Besifloxacin 0.6%	А	32 μL was instilled Group 1: after 10 minutes eyes removed. Group 2: after 1 hour eyes removed	Intact	Group 1: 6.01 ± 1.43 (NA) Group 2: 5.51 ± 1.01 (NA)	Group 1: 5.04 Group 2: 4.83	Group 1: 1.70 ± 0.04 (NA) Group 2: 1.71 ± 0.08 (NA)	Group 1: 1.67 Group 2: 1.66	(10)
	Н	One drop 60 mins prior to CS.	Intact	NA	NA	0.13 ± 0.58 (0.0086)	0.0043	(12)
Ofloxacin 0.3% (if not otherwise noted)	Н	One drop of 15 and 10 mins prior to PK	Intact	10.77 ± 5.90 (NA)	6.79	0.13 ± 0.11 (NA)	0.06	(2)
	Н	One drop every 15 minutes for 5 doses and then every 30 minutes for 3 doses before CS.	Intact	NA	NA	2.06 ± 1.06 (NA)	1.34	(7)

	Н	Group 1: Three 3 x 1 drop at 2hr intervals 1 day prior and 3 drops at 1h intervals on the day of CS.  Group 2: Nine times 1 drop at 15-minute intervals on the day of CS.	Intact	NA	NA	Group 1: 0.304 ± 0.204 (Range 0.031 - 0.984) Group 2: 0.564 ± 0.372 (Range 0.064 - 1.455)	0.16	(8)
	Н	Enucleated eyes immersed in 0.5% Ofloxacin for 10 minutes.	Intact	6.48 with standard error 0.613 (95% CI 5.37 - 7.78)	4.73	1.26 with standard error 0.127 (95% CI 1.02 - 1.53)	0.93	(9)
Gatifloxacin 0.3%	Н	Two drops administered three times prior to PK	Intact	4.71 ± 3.39 (4.44)	2.22	0.65 ± 0.80 (0.41)	0.20	(11)
	А	45 μL was instilled  Group 1: after 10 minutes eyes removed  Group 2: after 1 hour eyes removed	Intact	Group 1: 4.35 ± 2.61 (NA) Group 2: 2.36 ± 2.45 (NA)	Group 1: 2.59 Group 2: 0.71	Group 1: 0.06 ± 0.00 μg/g (NA) Group 2: 0.10 ± 0.08 μg/g (NA)	0.06	(10)
	Н	One drop every 15 mins for four doses prior to CS.	Intact	NA	NA	0.12 ± 0.076 (0.117)	0.058	(12)

#### References:

- 1. Kaye SB, Neal T, Nicholson S et al. Concentration and bioavailability of ciprofloxacin and teicoplanin in the Cornea. Investig Ophthalmol Vis Sci. 2009;50(7):3176–84
- 2. Healy DP, Holland EJ, Nordlund ML et al. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. Cornea. 2004;23(3):255–63
- 3. Price FW, Whitson WE, Collins KS et al. Corneal tissue levels of topically applied ciprofloxacin. Cornea. 1995;14(2):152–6.
- 4. McDermott ML, Tran TD, Cowden JW et al. Corneal Stromal Penetration of Topical Ciprofloxacin in Humans. Ophthalmology. 1993;100(2):197–200
- 5. Bucci FA. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. Am J Ophthalmol. 2004;137(2):308–12
- 6. Colin J, Simonpoli S, Geldsetzer K. Corneal penetration of levofloxacin into the human aqueous humour: a comparison with ciprofloxacin. Acta Ophthalmol Scand. 2003;81(6):611–3
- 7. Yalvac IS, Basci NE, Bozkurt A et al. Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous. J Cataract Refract Surg. 2003 Mar 1;29(3):487–91
- 8. Beck R, Van Keyserlingk J, Fischer U et al. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes. Graefes Arch Clin Exp Ophthalmol. 1999;237(2):89–92
- 9. Silva GCM, Jabor VAP, Bonato PS et al. Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into the cornea and aqueous humor of enucleated human eyes. Brazilian J Med Biol Res. 2017;50(7)
- 10. Domingos LC, Moreira MVL, Keller KM et al. Simultaneous quantification of gatifloxacin, moxifloxacin, and besifloxacin concentrations in cornea and aqueous humor by LC-QTOF/MS after topical ocular dosing. J Pharmacol Toxicol Methods. 2017;83:87–93



- 11. Fukuda M, Yamada M, Kinoshita S, Inatomi T, Ohashi Y, Uno T, et al. Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty. Adv Ther [Internet]. 2012 Apr [cited 2021 Nov 15];29(4):339–49
- 12. Donnenfeld ED, Comstock TL, Proksch JW. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. J Cataract Refract Surg. 2011;37(6):1082–9